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Figure 1. Distribution of patients in ESID (European Society of Immunodeficiencies) register by classification of PID (Primary iImmunodeficiency disease). (A) Absolute number and absolute numbers of patients aged over 65 by classification. (B) Distribution of classification of PID illness in those patients aged over 65. (C) Classification of predominant antibody deficiencies in patients over 65.
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Abstract
Primary immunodeficiency disease (PID) has traditionally been viewed as a group of illnesses seen in paediatrics. New advances in diagnosis and treatment have led to an increase in the number of elderly PID patients. However, there is lack of research evidence to base clinical management in this group of patients. Management decisions often have to be based therefore on extrapolations from other patient cohorts or from younger patients.  Data from the European Society for Immunodeficiencies (ESID), demonstrates that the vast majority of elderly patients suffer from predominantly antibody deficiency syndromes. We review the management of PID disease in the elderly, with a concentration on antibody deficiency disease.










Introduction

Primary Immunodeficiency Diseases (PID) are a heterogeneous group of conditions that lead to an increased susceptibility to infections. They are considered primary because the fundamental disease process arises within the immune system itself. Previous attention to immunodeficiencies in the elderly has been largely confined to secondary forms of disease, which are more common. However, with recent extensions of diagnostic nets, and improvements in clinical management, it has become more pressing to consider the importance of PID in the elderly. Data from the European Society for Immunodeficiency’s (ESID) register demonstrates that as of 5th November 2012, there are  692 patients registered with PID in Europe over the age of 65 and this makes up to 8% of the total patients registered (Figure 1).  This paper aims to discuss the management of antibody deficiency in this group of patients.  

A systematic literature search was carried out using PubMed and the Cochrane Database of Systematic Reviews from January 2008 to January 2012.  Key terms used were (primary immunodeficiency or PID) and (elderly or older).  The last search date was 8th January 2012.  Reports were excluded if they were not in English or had an English translation, and if the article did not pertain to human subjects.  Single case reports were included, so as to allow for the inclusion of adverse effects of medication administered.  All titles and abstracts were screened for 'relevance' and those deemed to be were examined more closely.  

PID diseases are classified according to which component of the immune system is impaired (Figure 1). Within this classification there are individual subsets, of varying relevance to the elderly population.  ADDIN EN.CITE [1]  

The immune system is a network of cells and proteins, predominantly derived from the haematopoetic system, which serves to protect the host from infection. It has traditionally been described under two main headings: innate and adaptive. Together, these provide both immediate host defence against infection and immunological memory, which protects against secondary encounters with the same pathogen. The innate immune system is composed both of cells, such as dendritic cells and macrophages, and proteins such as complement and C-Reactive Protein (CRP), which are capable of recognising a dangerous pathogen and so triggering the adaptive response. The adaptive response can be divided into cell mediated and humoral arms. It is based on the clonal selection of infrequent antigen-specific cells, which undergo a vast selective expansion in order to generate the numbers necessary to control the infection. The T cells of the cell-mediated arm of the adaptive immune system protect the host, either by directly killing the infected host cells, or by the secretion of cytokines that enhance immune responses. The humoral adaptive response is composed of B cells, which achieve ‘effector function’, the secretion of antibodies. These antibodies primarily serve to protect the host against extracellular pathogens but their protective role against intracellular pathogens has also recently been appreciated.[2] The adaptive response is completed by further interaction with the innate system, which takes the form of the recruitment and activation of both phagocytic cells (e.g. neutrophils and macrophages) and non-phagocytic cells (e.g. mast cells) to provide both immediate resolution and tissue-resident memory of the pathogen. 

The majority of the conditions in the above classification of PID present in childhood and are associated with severe life-threatening infections, which respond to treatment by bone-marrow transplantation. Long-term data on the safety of transplantation for PID is only recently being generated but results are encouraging. However, since transplantation treatment for PID only became available in most countries in the early seventies, the first cohort of successfully treated patients are still decades away from being in the elderly category. It is therefore unknown what primary disease manifestations, or complications of treatment, this group of patients may yet develop and follow-up throughout the life of these patients is important. [3]


The largest group of PID patients currently encountered in elderly care settings are those suffering from some form of antibody deficiency (Figure 1). Primary antibody deficiency syndromes are defined by the inability to make an effective immunoglobulin response.  Immunoglobulins are produced by plasma cells that are terminally differentiated B lymphocytes.  B lymphocytes are produced from the bone marrow and derived from a common lymphoid progenitor. During bone marrow maturation the B lymphocyte undergoes gene rearrangement of its antigen receptor to generate naïve B cells that have differing antigen specificities. These naïve B cells circulate between the tissues, blood stream and lymphatics, surveying the body for potential pathogens. Following the presentation of antigen in the lymph node, the adaptive B cell response is initiated (contingent upon appropriate signals being received from the innate immune system). The antigen-specific B cells, which are initially few in number, will undergo massive proliferation in the germinal centre reaction. During this reaction, mutations appear within the antigen-specific receptor (in a process termed somatic hyper-mutation) and this leads to the appearance of B cells that bear antigen-specific receptors of differing affinity from that of the parent cell.  B cells which carry mutations that lead their antigen-specific receptors to bind to the antigen with higher affinity preferentially receive survival signals denied to those cells that carry mutations which lead to antigen-specific receptors of weaker affinity. At the end of this proliferative response, many B cells appear which carry receptors that bind to antigen with greater affinity than those few B cells present at the beginning of the response that carried receptors which bound antigen with relatively weak affinity. From this germinal centre reaction, some B cells will undergo the final stage of differentiation, in which they become antibody producing plasma cells.  The antibody is a secreted form of the antigen-specific receptor of the B cell and is made up of five different classes, which carry differing functional responsibilities. By gene rearrangement, the part of the molecule which recognizes antigen can be recombined with chains that confer the functionality of the antibody molecule. IgM fulfills the role of initial intravascular pathogen binding and the activation of complement, whilst secondary immune responses with IgG, IgE or IgA are important for quick and efficient protection against pathogens.  IgG within the intravascular space is involved in complement activation and opsonisation.  It also provides the immune system with a memory against the pathogen and is an important component for successful vaccination.  IgE, on the other hand, is used by the host in defense of parasites, in particular protozoan based parasites, and helminths. IgA is thought to be important in the host’s defense of mucosal surfaces.  

Any defects occurring at any stage during the production of antibodies can have serious clinical consequences. Primary antibody deficiency, unlike many other PIDs, can present at any age, with peaks in childhood and the third decade of life.  ADDIN EN.CITE [4, 5]  It is important that secondary causes of immunodeficiency are ruled out, since these are relatively common and specific treatment aimed at these causes may be necessary.

X-linked agammaglobulinaemia 
X-linked agammaglobulinaemia (XLA), due to a mutation in the Bruton’s tyrosine kinase, leads to a failure in the maturation of naïve B cells in the bone marrow, which subsequently leads to a failure of antibody production. Presentation occurs with the loss of maternally transferred antibodies between 6 to 9 months of age. However, there tends to be a significant diagnostic delay for this condition: a recent study has shown that, in those patients with a significant family history of XLA, the average age of diagnosis was 2.59 years, while in those without, it was 5.37 years.  ADDIN EN.CITE [6] Few patients are, however, seen in elderly care settings: the condition was first described by Bruton in 1952 [7] and there was significant early mortality from XLA in the era prior to effective therapy. Yet, although most patients do present in childhood, there remains a significant proportion of patients that present and are diagnosed at a more advanced age, with the oldest reported sufferer being diagnosed aged 51.[8] This, together with data from recent series from Europe and America, suggests that many XLA patients will continue to need care well into retirement. ADDIN EN.CITE [6, 9] In our cohort of XLA patients at Royal Free Hospital, the oldest patient is aged 59 years old with the only complication being that of bronchiectasis.  The mainstay of therapy is replacement of intravenous immunoglobulin and immediate and sufficient treatment of break-through infections with antibiotics.


Common Variable Immunodeficiency
Common Variable Immunodeficiency (CVID) is the most common PID that leads to a reduction of serum immunoglobulin in adulthood.  CVID affects both men and women equally, with reported prevalence’s being between  0.5 to 10 per 100,000. ADDIN EN.CITE [10, 11]  It commonly presents with recurrent respiratory infections.  Unfortunately the diagnostic delay from the onset of initial symptoms until diagnosis is reported to be 5-6 years in the US and 4 years in Europe. ADDIN EN.CITE [5, 12]  Often these initial symptoms are managed by primary care physicians and, unless there is particular cause for clinical suspicion, then a diagnosis can be missed for up to a decade.  ADDIN EN.CITE [13] 

Unlike most other PID, CVID can manifest in childhood but remain undiagnosed until adulthood. Current diagnostic criteria for diagnosis with CVID includes age over 2 and an impaired immunity that cannot be explained by known genetic causes of antibody deficiency.[14]  Sinopulmonary infections are the most common clinical presentation, with patients also suffering from bronchitis, sinusitis, otitis, and up to two thirds suffering from pneumonia.  A study in 1993 in the UK showed that between 75-90% of CVID manifests as lower and upper respiratory tract infections.  The most common infections are organisms such as Streptococcus pneumoniae  ADDIN EN.CITE [15] and Haemophilus influenzae.  These recurrent infections often lead to bronchiectasis.  Pulmonary fibrosis, and granulomatous infiltration causing interstitial pneumonia are common, not necessarily infective complications of CVID.   

Approximately 20% of CVID patients suffer from gastrointestinal tract symptoms.  If they are of an infectious origin, they are often caused by Salmonella and Campylobacter [5].  Histological examination showed 19% of affected patients had granulomas and 30% had pathological features resembling coeliac disease.  30% were found to have inflammatory bowel disease and 20% with nodular lymphoid hyperplasia. [5] 

Malignancy and CVID
Malignancy is common in CVID with an increased susceptibility to gastric carcinoma and lymphoproliferative disorders.  

Helicobacter pylori infection and Pernicious anaemia are recognized causative factors for gastric cancer. [48]  Both are common in CVID patients as i) the immune deficiency allows for Helicobacter pylori not to be efficiently cleared and ii) autoimmune conditions are per se more prevalent in CVID.   

Helicobacter pylori infection, a major gastric carcinogen, can lead to atrophic gastritis, metaplasia dysplasia and gastric carcinoma. [49]  Gastric investigations of CVID patients have commonly found helicobacter pylori infection and its associated histological complications on biopsy. [50]

Pernicious anaemia, associated with low vitamin B12 levels, is commonly due to antibodies directed against parietal cells and intrinsic factor.  Gastric atrophy, often initiated by Helicobacter Pylori, increases predisposition to this condition.   Diagnosis of pernicious anaemia can be easily confirmed with a urea breath test as autoantibody tests in CVID hold little significance due to the underlying antibody deficiency. 

A recent study [48] proposed that all CVID patients should be screened for Helicobacter pylori with a urea breath test at diagnosis of CVID and in addition annual B12 levels and iron studies looking for possible perncious anaemia.  Those with evidence of helicobacter pylori, low serum B12 levels, dyspeptic symptoms or unexplained weight loss should undergo a gastroscopy with biopsies including those from the antrum and fundus.  Subsequent endoscopies should be based on histological findings with a proposed surveillance of 5 years, 3 years, 1-3 years and 6-12 months for chronic antral gastritis, atrophic pan-gastritis, intestinal metaplasia and dysplastic lesions respectively. [48]  

Mucosal associated lymphoid tissue (MALT) lymphomas, low grade B cell non Hodgkin lymphomas (NHL), are composed of marginal zone related cells.  They may arise as a result of proliferation of lymphoid tissue in organs, secondary to chronic infectious or autoimmune stimulation.[51, 52]  There have been numerous extranodal cases reported in CVID patients.   The known association between Helicobacter pylori and gastric MALT lymphomas increases the likelihood of development of such lymphomas in CVID patients.

Patients with primary antibody deficiency are inherently more at risk of developing a malignancy and the age-adjusted normal cancer screening programs that apply nationally should also apply. [20]  In CVID there appears to be a 1.8-fold to 13-fold increase in malignancy beyond what can be explained by the genetic background of the patient  ADDIN EN.CITE [21].  The risk of cancer in patients with CVID also varies with age of on onset, under 16s have a 2.5% risk of cancer, while over 16s have an 8.5% risk [22].  


Respiratory complications and CVID
Screening for pulmonary abnormalities via a chest X-ray and lung function tests have been shown to fail to pick up on a significant number of patients with interstitial lung disease and granulomatous changes, both of which have been discernible on chest Computed Tomography (CT)  ADDIN EN.CITE [16]. Since recurrent CT scans can significantly increase the chances of the patients developing cancer [55], some hospitals recommend CT scanning only once every 4-5 years  ADDIN EN.CITE [17].   

It is important to remember that pre existing respiratory comorbidities are more likely to be evident in the older population.  This may complicate radiological findings with difficulty in deciphering how much of this is being contributed to by the underlying immunodefiency.  Diagnostic bronchoscopy and biopsies may be required in some patients.  

Patients with CVID, although they fail to mount an appropriate antibody response to pathogens, can still produce an autoimmune response i.e against their own gastrointestinal tract, endocrine system and haematological system. Hence many physicians encourage the use of endoscopy at time of diagnosis to screen for gastrointestinal complications, followed by annual ultrasound scans and annual H. pylori screening. 

Haematological Disease and CVID
Approximately 11% of CVID patients suffer from an autoimmune haematological disease. Roughly equal numbers of these were affected with autoimmune haemolytic anaemia (AIHA), immune thrombocytopenia (ITP) and Evans syndrome (AIHA and ITP)  ADDIN EN.CITE [18, 19].  For haematological complications, which often present as autoimmune cytopenias in primary antibody deficiencies, screening by full count has been recommended every 3-6 months for those patients on IVIG.  ADDIN EN.CITE [18, 19].

Central Nervous System and CVID
Infections of the central nervous system (CNS) can be the presenting complaint of a primary antibody deficiency as well as a complication.  Possible organisms noted include. Strep. pneumoniae, Escherichia coli, H. influenzae,  Neisseria meningitidis, Listeria monocytogenes and Staphlococcus Aureus [22].  Granulomas are seen in about 8-12% of CVID patients and can be found in the brain and behind the eye.  Encephalomyelitis disseminata is an important differential diagnoses. [56]

Rheumatological complications and CVID
Rheumatological complications include seronegative arthritis, which can manifest as a chronic low-grade infection or as immune-mediated connective tissue disease. These complications can, however, often be successfully managed by the instigation of immunoglobulin replacement therapy. [23]  Disease modifying anti-rheumatic drugs (DMARDs)  should also be considered where immunoglobulins are ineffective in symptomatic control. 

Dermatological manifestations and CVID
Dermatological manifestations of primary antibody deficiency are infrequent but may include: eczema related disorders, vasculitis, skin infections (viral, bacteria or fungal), and autoimmune disorders such as granuloma formation. A number of patients have presented with alopecia and urticaria and associated infections such as herpes zoster. [24]

Vaccinations in CVID
Conjugate vaccination has the opportunity to elicit T cell memory responses, how protective this is debatable.  Live vaccines are contraindicated in all CVID patients.  Inactivated vaccinations can be safely given allowing protection for the elderly against pneumonia and flu over the winter months.  Inability to form an adequate or absent response to polysaccharide antigens has skewed preference towards conjugated vaccines. Immunoglobulin treatment allows transfer of specific antibodies from donors therefore dampening the risk of infection following exposure to those who have received live vaccines or who have had infections.   

Good’s syndrome
Another condition classified as a PID, although it shares many features of secondary immunodeficiency, is Good’s syndrome.  ADDIN EN.CITE [1] This syndrome is an adult onset immunodeficiency typified by thymoma and hypogammaglobulinaemia. The pathogenesis is unknown but a variety of features of immune-dysregulation can be observed, including low B cell numbers, anaemia, myasthenia gravis, leucopenia, and functional and quantitative T cell immunodeficiency. The complications show considerable heterogeneity across sufferers. Although this is a rare condition, it is of particular relevance to this review in light of its mean age of onset, which is the greatest for any PID: currently 59 years. [25] Together with the finding that 1-2% of adult patients treated with IVIG have Good’s syndrome, this suggests that the condition may make up a significant proportion of PID disease seen in the elderly. [26] The mainstay of treatment is replacement immunoglobulin but the associated T cell defects seen in many of these patients merits close monitoring for opportunistic infections. It has recently been noted that auto-antibodies produced as part of the immune-dysregulation in Good’s syndrome include auto-antibodies produced to cytokines and this may be a contributing factor in the unusual frequency with which these patients suffer from candidal disease. 

Management and Treatment

IVIG
The mainstay of specialist treatment for PID in the elderly is the provision of replacement immunoglobulin, which has been shown both to improve rate of infections and health-related quality of life (HRQoL). Replacement therapy with transfusion of -globulin has been in use since the late 1940’s [7] and is now the standard therapy for most PIDs, including: XLA,  severe combined immunodeficiency (SCID), CVID, Good’s syndrome, Wiskott-Aldrich syndrome, selective IgG  deficiency and X-linked hyper-immunoglobulin (IgM) syndrome [27].  Trials have shown that IVIG therapy can reduce the rate of bacterial infection, hospital admissions, days of antibiotics required to treat flare-ups and days of pyrexia  ADDIN EN.CITE [28].  This is particularly important to the elderly, who are vulnerable to hospital acquired infections and for whom the consequent antibiotic treatment increases the likelihood of succumbing to complicating infections such as Clostridium difficile (​http:​/​​/​en.wikipedia.org​/​wiki​/​Clostridium_difficile​).  

For the production of -globulins, plasma from donors is screened against common plasma-borne viruses such as Human Immunodeficiency Virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), parvovirus B19 and West Nile Virus.  Intra-muscular delivery is no longer carried out due to its painful administration and the consequent limitation of dose. Treatment is currently administered either by intravenous (IVIG) or sub-cutaneous (SCIG) routes. A UK-Swedish trial in 2000 showed no difference in the tolerability or efficacy of these routes  ADDIN EN.CITE [29].  However, more recent SCIG preparations have demonstrated better pharmacokinetic profiles and more favorable HRQoL, with an equivalent efficacy as intravenous IVIG [30, 31].  A trial from 2010 showed that SCIG was safe to use in the elderly and was well tolerated, including by those with diabetes. No adverse reactions (loss of diabetic control, exacerbations of heart failure, pulmonary symptoms, or renal disease) were noted [30]. SCIG may therefore prove the better option for elderly patients, who are more likely to have confounding co-morbidities such as diabetes, heart failure, hypertension, hypercholestaemia, chronic kidney disease, arthritis and dementia. SCIG can be used as either initial treatment or as a ‘salvage’ therapy for patients who do not tolerate IVIG [31].  There are, however, some concerns; for example, sufficient manual dexterity for self-infusion at home may be lacking [32] as seen in those with neurological impairment or rheumatological conditions. 

IVIG and SCIG doses are based on body weight.  Commonly both are given at a maintenance dose of 0.4 – 0.6 g/Kg per month with IVIG therapy given every three to four weeks [53] whereas SCIG is given more frequently, usually every week.  Increased immunoglobulin doses (up to 2g/kg) may be needed in those with protein losing conditions i.e. enteropathy, autoimmune conditions and in those with severe infections i.e. encephalitis.  Such doses are given via the intravenous route in a controlled environment.  Infusion rates are guided as by local pharmacy guidelines or product individual summary of product characteristics (SPC).  Slower rates may be required if adverse reactions are reported or if there are pre existing medical comorbidities such as cardiac failure or hyperviscose states.     The maximum immunoglobulin dose per day is dependent on patient tolerability and the maximum infusion rate as per the SPC as well as patient tolerability.  In the elderly, smaller doses and/or slower rates may be preferable especially in those with underlying medical conditions or history of thromboembolic events.  Patients receiving immunoglobulin therapy in a hospital environment should be kept under observation during their infusion.  Attending medical and nursing staff should be alert for the development of signs suggestive of a thromboembolic event or of an adverse reaction.  Patients should seek medical help if they become symptomatic post infusion.

For all immunoglobulin treatments, there is concern that likely co-morbidities (renal, hepatic and cardiovascular impairment, for example) in the elderly population may result in more frequent and severe adverse events than in younger patients.[30].  

Use of immunoglobulin is associated with a range of side effects ranging from mild fever and headache to anaphylactoid reactions. To monitor for these, the initial administration of immunoglobulin usually takes place in a medical facility and is carried out by  trained heath care professionals. A number of minor adverse events in the elderly can be prevented by premedication with paracetamol, diphenhydramine and even small doses of IV corticosteroids  ADDIN EN.CITE [33, 34].  It must be noted, however, that diphenhydramine use in the elderly has been linked with sedation, urinary retention and delirium.[35] Headaches commonly accompany the treatment and their management is complicated in the elderly population for whom use of non-steroidal anti-inflammatory based drugs is at times contraindicated. Treatment options for immunoglobulin infusion related headache are often reduced to slowing the rate of infusion and symptomatic treatment with paracetamol. 

Two particular adverse events encountered by the elderly population receiving treatment with immunoglobulin are renal failure and thromboembolic events. The renal problems are thought to be attributable to the sugar-based stabilizing agent used in many preparations of immunoglobulin, which can induce an osmotic injury in the proximal renal tubules. Therefore, in elderly and other patients whose renal function is suspected to be compromised, we recommend preparations of immunoglobulin which have a low sugar content. The thromboembolic adverse events reported include both arterial and venous systems, and can lead to deep vein thrombosis, stroke and heart-attack. Thromboembolic events are rare in patients aged less than 50; those that suffered arterial thrombosis had a mean age of 66, compared to 45 for venous thrombosis.  The most common co-morbidity from which these patients suffered was hypertension and coronary disease [36].  One study found that 11.8% of elderly patients experienced a thromboembolic event. While no single cardiovascular risk factor significantly increased the risk of having such an event, 4 or more such factors increased the risk 10-fold [37]. 

In elderly patients, consideration should be given to the immunglobulin product choice especially in those with poor diabetic control, congestive cardiac failure and history of thrombotic events.    There are no guidelines on the use of immunoglobulin therapy and diabetic management.  Most products contain insufficient amounts of sugar based agents to significantly affect the blood glucose.  Those products that can give false readings due to higher levels of maltose should be avoided as this can lead to unnecessary insulin administration and hypoglycaemic complications.   Product volume and concentration are important factors in managing those with cardiac failure or history of thrombotic events.  Low volume products are preferable for the former whereas low concentration products for the latter.  

Other Treatment Options:

Prophylactic Antibiotics
Treatment with antibiotic prophylaxis is considered in PID patients when, despite optimised other treatments such as immunoglobulin replacement, infections are still frequent or severe. These infections should be microbiologically confirmed wherever possible.  Consideration should be given to non-infective causes for symptoms such as a chronic cough and sore throat, for example, reflux, steroid inhalers, asthma, post-nasal drip, or post-infective bronchial hyper-reactivity.  Equally, patients with a chronic cough may have developed bronchiectasis. There is a lack of randomized controlled data on the benefit of antibiotic prophylaxis in the PID population with or without bronchiectasis. Clinical guidelines are therefore adopted from evidence gained from other patients groups such as those suffering from cystic fibrosis, which like untreated antibody deficiency leads to bronchiectasis, and from immunosuppressed patients, who also have increased susceptibility to infection. A number of trials have shown that azithromycin prophylaxis leads to an improvement in lung function in patients with cystic fibrosis[38] and Levofloxacin has been shown to reduce the incidence of fever, probable infection and hospitalization in patients receiving cyclic chemotherapy for solid organ tumours or lymphoma. ADDIN EN.CITE [39] Information gained from cystic fibrosis patients suffering from pseudomonas infection shows that inhaled prophylactic antibiotics provide antimicrobial protection for the conductive zone, whilst very little reaches the respiratory zone. The converse is true of systemically applied antibiotics[40], suggesting that both should be combined in PID patients with bronchiectasis colonized by pseudomonas. PID patients with evidence of T cell dysfunction should be placed on prophylaxis with co-trimoxazole, for which there is growing evidence of a successfully protective effect in non-HIV infected immunosuppressed patients. [41] Adequate trough IgG levels should be documented for immunoglobulin-treated individuals with recurrent infections.  There are no specific guidelines for trough levels but generally trough levels should be aimed to be greater than the lower limit of the normal IgG range.  Higher trough levels may be required in those with repeated or severe infections despite ‘adequate’ trough levels.  Chapel et al proposed that immunoglobulin dosing should be directed by the number of breakthrough infections in each individual patient rather than aiming for a particular trough level [54].  For those not receiving replacement therapy, a constant review of symptoms, exacerbation frequency, microbiology, lung function and vaccine responses is required, to assess whether or not immunoglobulin becomes necessary. 

Chest physiotherapy, flutter valves and sputum induction should be considered in the management of those with underlying structural lung disease in order to help optimise respiratory function.  Bronchoscopy may be needed in those with resistant symptoms or widespread radiological changes.   However, in the elderly poplulation, this investigation may not always be as simple especially in those with poor oxygenation, underlying cardiac disorders or coagulopathies.   Non invasive investgations such as  lung function tests can prove a beneficial tool in assessing response to treatment.   

It should be remembered that repetitive use of corticosteroids to treat respiratory exacerbations can lead to the well known side effects of long term corticosteroid use.  Recurrent corticosteroid treatment may be also be needed in those with certain haematological and gastroenterology complications of CVID.   

Bone marrow transplation and gene therapy
Although, as mentioned previously, the first cohort of PID patients treated in childhood with bone marrow-transplantation have not yet reached old age, we can consider some of the probable effects of bone-marrow transplantation as used recently in individual adult patients for the treatment CVID and Wiskott-Alrdich syndrome.  ADDIN EN.CITE [42, 43] Transplantation was considered successful in 3 out of the 4 CVID patients treated; in 1 patient it lead to treatment related death. In 2 of these patients the primary indication for transplantation was lymphoproliferative disease, for the other 2 it was end-organ damage related to CVID. Three of these patients had improvements in their symptoms of immunodeficiency and one patient was able to stop immunoglobulin therapy post-transplant and continued to maintain serum immunoglobulin and remain infection free. These cases demonstrate that, although transplantation remains a high-risk procedure, it is likely to be used with increasing frequency in carefully selected groups of adult patients. The challenge now is to develop methodologies to stratify adult PID patients into those groups that may benefit from this high-risk treatment, where a bone marrow donor is available. In cases where a donor is unavailable, there may be in future some alternative routes for treatment. Increasing information available regarding the single gene defects which lead to primary immunodeficiency [44] and CVID in particular  ADDIN EN.CITE [45] opens up the possibility for curative gene therapy approaches. However, the significant risk of leaukaemic transformation seen in the children treated with gene therapy for PID  ADDIN EN.CITE [46] has so far limited further research into this therapeutic modality. 

Conclusions
The greater awareness that infectious diseases can be attributable to host factors[47], combined with improvements in mortality and morbidity attributable to PID will lead to PID being seen more frequently in the elderly population. The mainstay of treatment for PID in this age group remains immunoglobulin replacement and symptomatic treatment aimed at the causative pathogens. Data needs to be generated to assess in which elderly patients this treatment is insufficient. At present curative procedures such as gene therapy and bone-marrow transplantation are either experimental or associated with high mortality in this population. Therefore it is only when the data becomes available allowing us to stratify patient subgroups and to predict in which ones current optimal treatment is insufficient that these newer treatment modalities be utilized in the elderly population. 
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